Reading, MA, United States of America

Michael A Sandberg

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael A Sandberg: Innovator in Gene Therapy

Introduction

Michael A Sandberg is a notable inventor based in Reading, MA (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of retinal diseases. With a total of 2 patents, Sandberg's work focuses on innovative methods to address critical ophthalmological conditions.

Latest Patents

Sandberg's latest patents include groundbreaking methods for treating human subjects with X-linked Retinitis Pigmentosa (XLRP). His approach involves administering a nucleic acid that comprises an adeno-associated viral vector containing an abbreviated human RPGR cDNA. This method aims to provide effective treatment for individuals suffering from this genetic condition, which leads to vision loss.

Career Highlights

Throughout his career, Michael A Sandberg has worked with esteemed organizations such as the Massachusetts Eye and Ear Infirmary and UCL Business Plc. His experience in these institutions has allowed him to collaborate with leading experts in the field of ophthalmology and gene therapy.

Collaborations

Some of Sandberg's notable coworkers include Basil Pawlyk and Alan Finlay Wright. Their collaborative efforts have contributed to advancing research and development in gene therapy.

Conclusion

Michael A Sandberg's innovative work in gene therapy exemplifies the potential for scientific advancements to improve the lives of individuals with genetic disorders. His contributions continue to pave the way for future research and treatment options in ophthalmology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…